OTHER × Lymphoma, Non-Hodgkin × Bendamustine Hydrochloride × Clear all Haploidentical BMT With Post-Transplant Cyclophosphamide and Bendamustine
Phase 1 Completed
50 enrolled
CPI-613 in Combination With Bendamustine in Patients With Relapsed/Refractory T-Cell Non-Hodgkin Lymphoma
Phase 2 Terminated
6 enrolled 13 charts
Combination of Pentostatin, Bendamustine and Ofatumumab for Treatment of Chronic Lymphocytic Leukemia and Lymphoma
Phase 1 Terminated
10 enrolled
Bendamustine + Obinutuzumab Induction With Obinutuzumab Maintenance in Untreated Mantle Cell Lymphoma
Phase 2 Terminated
21 enrolled 17 charts
Bendamustine Plus Rituximab Versus Fludarabine Plus Rituximab
Phase 3 Completed
230 enrolled
Bendamustine and Rituximab Induction Therapy and Maintenance Rituximab and Lenalidomide in Previously Untreated CLL/SLL
Phase 2 Completed
36 enrolled 11 charts
BRiM
Phase 1 Completed
11 enrolled 20 charts
Bendamustine and Rituximab in Combination With Copanlisib for the Treatment of Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Phase 2 Terminated
1 enrolled 6 charts
Carfilzomib With Bendamustine and Rituximab in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma
Phase 1 Completed
10 enrolled
Bendamustine Bridge to Autologous or Allogeneic Transplant for Relapsed/Refractory Lymphoma
Phase 1/2 Completed
34 enrolled 22 charts
Bendamustine, Mitoxantrone, and Rituximab (BMR) for Patients With Untreated High Risk Follicular Lymphoma
Phase 2 Terminated
14 enrolled 10 charts
BRP
Phase 1 Completed
33 enrolled 13 charts
R-BMD in Refractory or Relapsed Lymphoma, GELTAMO Clinical Trial
Phase 2 Completed
61 enrolled 8 charts
CPI-613, Bendamustine Hydrochloride, and Rituximab in Treating Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma
Phase 1 Terminated
1 enrolled
BeEAC-1
Phase 2 Unknown
100 enrolled
IIL INFL09
Phase 2 Completed
73 enrolled
Bendamustine Hydrochloride, Etoposide, Dexamethasone, and Filgrastim For Peripheral Blood Stem Cell Mobilization in Treating Patients With Refractory or Recurrent Lymphoma or Multiple Myeloma
Phase 2 Completed
43 enrolled 5 charts
Bendamustine Hydrochloride, Clofarabine, and Etoposide in Treating Younger Patients With Relapsed or Refractory Hematologic Malignancies
Phase 1 Completed
16 enrolled
BEB Conditioning Regimen for Autologous Stem-cell Transplantation(ASCT) in Non-Hodgkin's Lymphoma
Phase 2 Unknown
20 enrolled
Study of IPI-145 in Combination With Rituximab or Bendamustine/Rituximab in Hematologic Malignancies
Phase 1 Completed
48 enrolled
BVR
Phase 2 Completed
31 enrolled 9 charts
Bendamustine and Bortezomib Combination Therapy in Indolent Non-Hodgkin's Lymphoma(NHL)
Phase 1/2 Completed
12 enrolled 6 charts
Phase I BLR
Phase 1 Completed
28 enrolled
Gene Therapy for B-Cell Non-Hodgkin Lymphoma Using CD19 CAR Gene Transduced T Lymphocytes
Phase 1/2 Unknown
18 enrolled
Dexamethasone, Ofatumumab and Bendamustine (DOT) First-line in Mantle-cell Lymphoma(MCL)
Phase 1/2 Unknown
50 enrolled
Clinical Protocol for the Treatment of Patients With Previously Untreated Chronic Lymphocytic Leukemia With a Combination of Bendamustine and Ofatumumab
Phase 2 Terminated
1 enrolled
PH2 Trial in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL) With a Combination of Bendamustine & Ofatumumab
Phase 2 Withdrawn
37 enrolled
Bendamustine and Temsirolimus in Patients With Relapsed or Refractory Mantle Cell Non-Hodgkin's Lymphoma (NHL)
Phase 1/2 Withdrawn
20 enrolled
Treatment of Patients With Relapsed or Primary Refractory Aggressive B- Cell NHL
Phase 2 Unknown
30 enrolled